AbCellera Secures Major Collaboration with Jazz Pharmaceuticals for T-cell Engagers
ABCL has more than doubled off its 52-week low of $2.745.
Summary
AbCellera announced a preclinical research collaboration with Jazz Pharmaceuticals, including $56 million upfront and up to $792 million per program in potential milestones, to discover and develop T-cell engaging multispecific antibodies for various cancers.
Key Events · M&A and Partnerships · ABCL
-
Collaboration with Jazz Pharmaceuticals
AbCellera entered a preclinical research collaboration, option, and license agreement with Jazz Pharmaceuticals to discover and develop next-generation T-cell engaging multispecific antibodies.
-
Significant Upfront Funding
AbCellera will receive $56 million in total upfront payments for two initial research programs, with an additional $28 million due upon initiation of a third program.
-
Substantial Milestone Potential
The agreement includes eligibility for up to $792 million per program in option fees and development, regulatory, and commercial sales milestone payments, plus tiered royalties on net sales.
-
Oncology Focus
The collaboration targets multiple gastrointestinal cancers and other solid tumors, leveraging AbCellera's antibody discovery engine and T-cell engager platform.
Analysis · ABCL · Life Sciences
This collaboration with Jazz Pharmaceuticals provides AbCellera with a substantial upfront payment and significant potential milestone payments, validating its T-cell engager platform and providing non-dilutive funding for its oncology pipeline. The agreement covers multiple programs in high-value cancer indications, significantly expanding AbCellera's development opportunities.
At the time of this filing, ABCL was trading at $5.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $2.75 to $6.79. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.